EMERYVILLE, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has entered into a product development and production agreement for Vitamin A with Koninklijke DSM N.V. (Royal DSM) (AEX:DSM.AS), the global science-based company active in health, nutrition and materials. This marks the second such agreement between the two parties.
DSM is partnering with Amyris to fund the development of the technology to produce Vitamin A on a cost-advantaged basis utilizing Amyris’s and DSM’s capabilities. Once scaled, DSM will take the product to market utilizing its global channel and market access for animal and human nutrition and health. Amyris will develop, scale and produce a key ingredient for Vitamin A to supply exclusively to DSM.
"We are pleased to announce our second major product development and production agreement with DSM that we expect will end up being one of several going forward. This agreement is consistent with our collaboration business model and includes payment for development and value share on product production and delivery,” said John Melo, Amyris President & CEO. "Our partnership with DSM is a key example of our disruptive business model that leverages Amyris technology to achieve cost-advantaged product innovation with a successful global partner that can rapidly scale sales. The results are expected to drive robust product sales growth for Amyris while continuing to support our partner’s competitive position."
About Amyris
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements regarding Amyris, and any statements regarding Amyris other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected production of Vitamin A on a cost-advantaged basis using Amyris technology, the anticipated commercialization of such product, expected future agreements between Amyris and DSM, the anticipated use of Amyris technology to achieve cost-advantaged product innovation with global partners that can rapidly scale sales, and expected Amyris product sales growth) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris's Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on August 14, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@Amyris.com
pr@Amyris.com